Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data

Acrivon Therapeutics, Inc. ( (ACRV) ) just unveiled an update.

On January 8, 2026, Acrivon Therapeutics reported updated Phase 2b data for its CHK1/CHK2 inhibitor ACR-368 in endometrial cancer, with an interim analysis as of December 4, 2025 showing a 39% overall response rate in biomarker-positive monotherapy patients and a 44% rate in those with two or fewer prior lines of therapy; in the serous endometrial cancer subtype, confirmed response rates reached 67% in biomarker-positive patients and 52% across biomarker-positive and -negative subjects, prompting the company to refocus Arm 3 of the trial on serous patients with limited prior treatment and to expand this arm into more than 20 trial sites across Germany, Italy, France and Spain, with EU enrollment expected to begin in the first quarter of 2026 and overall Arm 3 enrollment completion targeted for the fourth quarter of 2026. The company also detailed progress in its broader pipeline, including initial Phase 1 results for ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, where 33 patients treated as of December 22, 2025 showed favorable tolerability and tumor shrinkage in 9 of 20 evaluable subjects—including partial responses in endometrial cancer, small cell lung cancer and squamous non-small cell lung cancer—and the nomination of ACR-6840, an AP3-derived CDK11 inhibitor, as its next development candidate with an investigational new drug application planned for late 2026, underscoring Acrivon’s drive to build a differentiated, AP3-enabled precision oncology franchise.

The most recent analyst rating on (ACRV) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Acrivon Therapeutics, Inc. stock, see the ACRV Stock Forecast page.

Spark’s Take on ACRV Stock

According to Spark, TipRanks’ AI Analyst, ACRV is a Neutral.

The score is held back primarily by weak financial performance (no revenue, large and persistent losses, and significant cash burn), partially offset by a strong technical uptrend and low balance-sheet leverage. Valuation provides limited support due to negative earnings and no dividend yield data.

To see Spark’s full report on ACRV stock, click here.

More about Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc., based in Watertown, Massachusetts, is a clinical-stage biotechnology company developing precision oncology medicines using its proprietary Generative Phosphoproteomics AP3 platform to guide rational drug design and predictive clinical development. The company focuses on first-in-class targeted therapies, including CHK1/CHK2, WEE1/PKMYT1 and CDK11 inhibitors, aimed at high unmet-need solid tumors such as endometrial cancer, small cell lung cancer and squamous non-small cell lung cancer.

Average Trading Volume: 790,599

Technical Sentiment Signal: Buy

Current Market Cap: $94.98M

For an in-depth examination of ACRV stock, go to TipRanks’ Overview page.